Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

“This data underscores SIL-204’s potential to address one of the most aggressive and challenging cancers, validating its ability to target KRAS mutations systemically while achieving prolonged therapeutic activity. While the current data shows robust tumor growth inhibition, further studies aim to evaluate its impact on metastases, which the Company is cautiously optimistic about.”